TARGeted Intraoperative radioTherapy (TARGIT) Registry Database

Early-Stage Breast Carcinoma Clinical Trial

— TARGIT R  

Official title:

TARGIT R: TARGeted Intraoperative radioTherapy (TARGIT) Registry Database

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02947425
• Other study ID #: TARGIT R
• Secondary ID: ISRCTN9117987514
• Status: Recruiting
• Start date: July 2013
• Est. completion date: July 2022

Study information

• Verified date: October 2019
• Source: University College, London
• Contact: Nick J Roberts
• Email: SITU.TARGITR[@]ucl.ac.uk
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This is a prospectively registered database of patients with early breast cancer who will be treated with radiotherapy during surgery. More than 2000 women have already received this treatment in clinical trials. This study will monitor the health status of women who receive this treatment outside of a clinical trial, especially those who might not have been eligible for the original clinical trials. The aim is to confirm the long-term effectiveness and safety of the technique.

Description:

Registration of patients selected for this treatment; collecting data regarding safety and toxicity on patients who have had treatment with TARGIT.

Outcomes will be measured over short and long terms. Outcome measures will include effectiveness and safety, assessed in various cohorts of patients. Core outcomes will be used for effectiveness. In addition, true recurrence (basically, ipsilateral breast tumor recurrence at the same site as the original primary) will be used as defined by Recht. Safety outcomes will be based on Common Toxicity Criteria.

Budget impact analysis of IORT in subgroups of patients will be assessed. This amounts to using cost data to calculate the mean incremental (or extra) cost per person treated using intraoperative radiotherapy (IORT) versus external beam radiotherapy (EBRT) and mastectomies (where IORT could have been given instead) and then multiplying this by the total patients eligible nationally for IORT, to calculate the total expected budget impact on the NHS if IORT in these subgroups was rolled out nationally.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: July 2022
• Est. primary completion date: July 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Recommended treatment by MDT

• Consent has been obtained to have patient data to be collected

Exclusion Criteria:

• Pregnancy (females who have a positive pregnancy test prior to surgery)

• Under 18 years of age

Related Conditions & MeSH terms

• Breast Neoplasms
• Early-Stage Breast Carcinoma

Locations

Country	Name	City	State
United Kingdom	Royal Free Hospital	London
United Kingdom	The London Clinic	London
United Kingdom	Royal Hampshire County Hospital	Winchester

Sponsors (1)

Lead Sponsor	Collaborator
University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Local tumour control (defined as no recurrent tumour in the ipsilateral breast)	Confirmation that the TARGIT technique results in an acceptably low rate of local recurrence when given outside of a randomised controlled trial.	Five years
Primary	Adverse events related to the primary treatment of the breast cancer.	Confirmation that the TARGIT technique results in an acceptably low rate of safety events assessed by CTCAE v4.0 when given outside of a randomised controlled trial.	Five years
Secondary	Cost effectiveness	Confirmation that the TARGIT technique is cost-effective as assessed by both health related quality of life (EQ5D) and cost data.	Five years